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106g-1591 Exolmer Laser Guldewlro Penetration ot the 
Imperforate Valve end Balloon Valvuloplaaty for  
Pulmonary Atrss!a With Intact Ventrlcular 
Septum 
M,P. Loung. A,K,T, Chau. Y, Choung, Paedlatnc Cardiology, Granttt~m 
He,p/tat. Un/v~rsity of Hong Kong, China 
Background: Establishing continuity between the right ventricle (RV) end 
pulmonary trunk promotes RV growth and subsequent blvontrlcular epair 
In babies with pulmonary atrosla and Intsct ventrlcul,r sepfttm (PAWS), We 
plonoored the g~s of aft Exctmor laser wire followed by balloon valvuloplasty 
(BV) fo achieve the purpose and reviewed our Initial exparlonco, 
Method: B~tw~an 1990 fo I097, 7 b~blsa (all neon(~tos except one 
8,monfh inl[tnf) underwent the above Interventions, Altar anglogr~ph,c onfir. 
marion of fha diagnosis, a 4.French end.hole guiding gatherer w~s lodged up 
the Inlundtbul~r c~vity (INF) thro~lgh whlcl~ a 0,018" Exclmor I~sor guldewlro 
was pa~sed ~nd tl~a energy of 60 mJImm ~ at 25 pulse/see was ,ppllod for 2 
s~o a~ the wire p~s~od through the Impedor~ts valve, The wlm was scoured 
tn fha descending aod(t and sequential BV podormod with batloon~ nlzod 
2'.,4 mm f011ownd by 6--9 mm tn dlametsm, 
Re~ult~: 2 pstlent~ had a n~rmwed INF of 2 ram; in f the wire pussnd 
into the porlc~rdtal cavity', In ~lnotltor the procedure was ~bandoned, B o! 
the O (85%) b~hto~ t~a(1 sttccnsslttl penetration el th~ tmpndorafn valve ~nd 
BV, The mofm follow (tp period was 09 :t 7,8 months end the changes in 
haemodyn~rol(~s and growth of the RV at the latest cathnteri;~ation (moon = 
4,0 months) worn: 
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Concluslon: Exetmor laser gutdowlro penetration el the impedorate valve 
followed by BV tS nn acceptable alternative truatmont for babies with PAWS. 
I 1069-160"].. Occlusion of  Patent Ductus Arter leaus With 
Lon9 Glanturoo Coi ls  (4-6 Loops)  Is Safe end 
Effective Without Detachment Mechanisms for  
up to 4,3 mm Ouctus Diameter 
W,A,K, Radtke, B,R, Waller, Medical University of Charleston. SC. USA 
Transcathefor occlusion of the patent ductus artoriosus (PDA) using Gi- 
~nfumo coll~ we.': attempted and accomplished in 108 ~atinnts with a median 
ago of 26 yrs (5 rags to 34 yrs) and a median weight of 127 kg (3.3 to 
84 1 kg) Smallest ductus dinmoto~ ranged from 0,4 to 4.3 mm (moan 1 6 
ram) Median fluoroscopy tLmo was 13,9 mtn (5.-.37 rain). One to 3 coils 
tmoon 1,2) were implanted mostly tmnsartorially, Coils with 4--6 loops were 
used m 90% and wore dolcvored witl~otri snare or forceps technique. One 
inadvodent ombolization occunod to the polmonan/artery (09%) in a patient 
with duchts sposm during angtographic measurement: pulse toss requiring 
TPA.lysts occurred in 1 (09%), No significant loll polmonary arian/or aortic 
arch stonosos were obsurved. Patlenfs worn discharged the same day in 
71%. Ductus closure was assessed by angiography after 10 rain, by color 
Doppler after 2-..12 hrs and 3-6 rags. Complete closure was achieved in 84% 
(911108) alter 10 rain, in 94% (1011108) allot 2-12 hrs end in 99% (74/75) 
after 3-6 rags. Ductus type, pallont age or weight, or hoparlntzation had no 
influence on occlusion rates. Residual shunt was significantly morn frequent 
with larger ductus diameters at 10 mtn (p = 0,001) af 2-12 hrs (p = 0,006) 
and at 3-6 rags (p = 0017), We conclude that franscatheter occlusion of the 
patent ductus arteriosus using long Giantumo coils with 4-6 loops ie safe 
nnd effective without detachment mechanisms for a, ductus types and sizes 
up to 4.3 mm smallest diameter. 
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~ Renal Function Is the Most Important D~.terminant 
of Survival In Patients With Severe Congestive 
Heart Failure 
A.RJ. Girbes, D.J. van Veldhuisen, P.J. de Kam. A. Charlesworth. 
J.R. Hampton. University Hospital Groningen. Netherlands: University 
Hospital Nottingham. UK 
Background: Congestive heart failure (CHF) is associated with a decrease 
of glomerular ilttrat;on rate (GFR) and - morn pronounced - of renal blood 
flow. loading to soctlum and water retention and decreased renal cleltranco 
of exogenous & endogenous compounds. 
Methods; Baseline GFR nf patlnnfa with NYHA Ill-IV. who took pert te 
the multlcontor ibopamlco survival trial (PRIME II). was estimated using the 
formula [(140-age in yr)/boe~., ~,,t Jr: kg)l/[72"semm cmatiblno in mgldl]~ In 
womun die calculated value was multiplied by 0,85. Multiple Cox regression 
analysis using backward selection was performed to cermet he effect of GFR 
on mortality far confounding variables, am use of dtumfics and CEI. tof~ther 
with Ksplltn.Meler survival analysis, 
Results: GFR could ba calculated in 1708 patients. GFR was the most 
important determinant for survival in the. PRIME II study, suq~ing  param. 
oIQ~ all LVI~F, NYHA classlticstion, concomitant rnedicatian, hypofe.nsion. 
presence el dlnbafas mnlllt,s, (~nd tachycotdit~,/~ ~FR -- 60 mltmin indicated 
a 2,1 risk ratio for mortality, 
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Conc/usion: GFR is the most important determinant o! sun~val in patients 
with ~ev0m CHF, even morn powedul fhnn cumontly established patamefem 
as LVEF, low BP and concomitant medication. 
~ Frequency and Adverse Impact o f  Mild Renal 
Dysfunct ion In Stable Heart Fai lure 
D,L. Dries, M.J. DomanskL LW. Stevenson. The National Heart, Lung and 
Blood Institoto, Bethe.~da, MD; The Bngham and Women ~ Hospatat, 
Boston, MA, USA 
Background: The prevalence and implications o! renal dysfunction in pabents 
with head lailum am not well described. 
Methods: To evaluate this issue, we conducted a retmspectwe analysis of 
the 6797 padtcipante in the SOLVD Prevention and Treatment Teals Sunnval 
tn patients with a baseline serum creattntne level (Cr) of 15-2.0 rag/all was 
compared to those with a Cr o! -~ 1.5 mgldL Patients with a Cr - 20 moJdl 
wore excluded from tee trials. 
Results; A total of 1024 patients (15%) had a Cr t 5-20 m(3~dl Pattie|- 
pants with a Cr 1,5-2.0 mgldl were older (64 vs.59 yrs). more likely to be mate 
(91 vs 85%). have NYHA class IWIV symptoms (20 vs 11%). diabetes (25 
vs 18%) Or peer hypedenston (51 vs 37%) [alt P .  0001] Average election 
traction was lower (26 vs 27%, P = 0.01) in the Cr 1.5-2.0 mg/dl group. The 
pmvateece of prior MI (72 vs. 75%) and angina (58 vs. 57%) was similar 
in the two groups, Diuretics (60 vs. 40%) and antiarrhythmics (28 vs. 16%) 
worn morn commonly used in patients with a Cr 1.5-2.0 mg/dL Enatapril use 
was equivalent (50%) in the two groups. Despite multivariate adjustment for 
baseline differences, a Cr 15-2.0 mgldl remained strongly associated with 
all-cause mortality (RR 1.41: 95% CI 1.25-1.59; P < 0.001), pump failure 
death (RR 1,50; 95% CI 1,25-,.1.80; P < 0,001) and a trend for an increased 
risk of sudden death (RR 1,28', 95% CI 0.99-1.63 P = 0.051 ). 
Conclusions: In patients with stable heart failure, mild renal impairment 
(Cr 1.5-2.0 mg/dl) is strongly associated with total mortality and disease 
progression manifested as pump failure death. 
~ U r l c  Acid as Independent Predictor  of  Impaired 
Prognos is  In Patients With Chronic  Heart Failure 
S.D. Anker, F. Leyva. P.A. Peele-Wilson, A.J.S. Coats. Cardiac Medicine, 
NHLI London. UK 
We have shown that serum uric acid (UA) is a marker of impaired oxida- 
tive metabolism, immune activation and endothelial dysfunction in CHF. We 
sought to determine, whether UA levels are therefore related to prognosis, 
and whether this wc~uld be independent of other risk factors (RF), Between 
1992 and 1996 we assessed in 112 CHF patients (age 59 + 12 y, peak 
VO~ 17.2 -~ 76.7 ml/kg/min, mean ~- SD) serum UA levels (495 ± 145 reel/I, 
range 187-930, age-matched healthy controls [mean ~: 2SD]: 320 ± 80). In 
96 patients also radionuclide left ventricular ejection fraction (LVEF) was as- 
sessed (26 ± 15%), During follow-up (m(,aa 693 ± 437 days, range 4-1505) 
35 events were recorded (32 deaths, 3 heart transplantations, 1-year event 
rate 20%, 2-years: 31%). Medication: 95% with diuretics, no patient was on 
allopurinol, 
